SCHEMBL3725124 — predicted protein targets

Predicted protein targets (top 20)

	gene	UniProt	supporting neighbours	confidence
▸	KDM4E	B2RXH2	2/20	0.34

▸	MAPT	P10636	2/20	0.34

▸	MEN1	O00255	1/20	0.34

▸	NPC1	O15118	1/20	0.34

▸	MAPK1	P28482	1/20	0.34

▸	KMT2A	Q03164	1/20	0.34

▸	NOD2	Q9HC29	1/20	0.34

▸	HSP90AA1	P07900	2/20	0.33

▸	CA12	O43570	1/20	0.33

▸	CA1	P00915	1/20	0.33

▸	CA2	P00918	1/20	0.33

▸	CA9	Q16790	1/20	0.33

▸	HPGD	P15428	2/20	0.33

▸	ALDH1A1	P00352	1/20	0.33

▸	SCN9A	Q15858	3/20	0.31

▸	FBP1	P09467	2/20	0.31

▸	LRRK2	Q5S007	2/20	0.31

▸	SMN1; SMN2	Q16637	1/20	0.31

▸	STAT3	P40763	1/20	0.31

▸	CYP3A4	P08684	2/20	0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL3929327	0.86	GAA (0.40)	KDM4EMAPTHSP90AA1CA12CA1
SCHEMBL3728132	0.85	PPARA (0.42)	KDM4EMAPTMEN1NPC1MAPK1
SCHEMBL3938174	0.85	CA1 (0.35)	KDM4EMAPTMEN1KMT2ACA12
SCHEMBL27861382	0.79	AAK1 (0.37)	MAPTMEN1MAPK1KMT2AHPGD
SCHEMBL3930800	0.78	VDR (0.34)	MAPTMEN1NPC1KMT2AHPGD
SCHEMBL12658712	0.70	HSP90AA1 (0.57)	HSP90AA1HPGDSMN1; SMN2TSHRHSD17B10
SCHEMBL30474394	0.70	HSP90AA1 (0.57)	HSP90AA1HPGDSMN1; SMN2TSHRHSD17B10
SCHEMBL2424582	0.69	LMNA (0.38)	KDM4EMAPTMEN1NPC1MAPK1
SCHEMBL23124788	0.69	FBP1 (0.41)	MAPTMEN1NPC1KMT2AHPGD
SCHEMBL30093499	0.69	FBP1 (0.41)	MAPTMEN1NPC1KMT2AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
CN-101553493-B	Tricyclic spiropiperidine compounds, their synthesis and their use as modulators of chemokine receptor activity	ASTRAZENECA AB	2012-07-04	—	—	CN	disclosed
WO-2010007408-A3	INTERMEDIATES 2-(2-CHLORO-5-HYDROXY-4-METHYLCARBAMOYLPHENOXY)-2-METHYLPROPIONIC ACID TERT-BUTYL ESTER AND GLYCIDYL BENZENE SULFONATES OR SALTS THEREOF AND THE PROCESS FOR PREPARATION OF SAID INTERMEDIATES	ASTRAZENECA AB (SE)	2010-05-06	—	—	WO	disclosed
WO-2010007408-A2	INTERMEDIATES 2-(2-CHLORO-5-HYDROXY-4-METHYLCARBAMOYLPHENOXY)-2-METHYLPROPIONIC ACID TERT-BUTYL ESTER AND GLYCIDYL BENZENE SULFONATES OR SALTS THEREOF AND THE PROCESS FOR PREPARATION OF SAID INTERMEDIATES	ASTRAZENECA AB (SE)	2010-01-21	—	—	WO	disclosed
WO-2010007408-A2	INTERMEDIATES 2-(2-CHLORO-5-HYDROXY-4-METHYLCARBAMOYLPHENOXY)-2-METHYLPROPIONIC ACID TERT-BUTYL ESTER AND GLYCIDYL BENZENE SULFONATES OR SALTS THEREOF AND THE PROCESS FOR PREPARATION OF SAID INTERMEDIATES	ASTRAZENECA AB (SE)	2010-01-21	—	—	WO	disclosed
US-20090176815-A1	Novel Tricyclic Spiropiperidine Compounds, Their Synthesis and Their Uses as Modulators of Chemokine Receptor Activity	ASTRAZENECA AB (SE)	2009-07-09	—	—	US	disclosed
US-20090176815-A1	Novel Tricyclic Spiropiperidine Compounds, Their Synthesis and Their Uses as Modulators of Chemokine Receptor Activity	ASTRAZENECA AB (SE)	2009-07-09	—	—	US	disclosed
US-20090176815-A1	Novel Tricyclic Spiropiperidine Compounds, Their Synthesis and Their Uses as Modulators of Chemokine Receptor Activity	ASTRAZENECA AB (SE)	2009-07-09	—	—	US	disclosed
EP-2069355-A1	NOVEL TRICYCLIC SPIROPIPERIDINE COMPOUNDS, THEIR SYNTHESIS AND THEIR USES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY	AstraZeneca AB (SE)	2009-06-17	—	—	EP	disclosed
WO-2009011655-A1	SPLROPIPERIDINE COMPOUNDS, A PROCESS OF THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THE TREATMENT OF AIRWAY DISEASES, INFLAMMATORY DISEASES, COPD OR ASTHMA	ASTRAZENECA AB (SE)	2009-01-22	—	—	WO	disclosed
WO-2009011655-A1	SPLROPIPERIDINE COMPOUNDS, A PROCESS OF THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THE TREATMENT OF AIRWAY DISEASES, INFLAMMATORY DISEASES, COPD OR ASTHMA	ASTRAZENECA AB (SE)	2009-01-22	—	—	WO	disclosed
WO-2009011654-A1	PROCESS FOR THE PREPARATION OF CYCLIC SPIROPIPERIDINES	ASTRAZENECA AB (SE)	2009-01-22	—	—	WO	disclosed
WO-2009011654-A1	PROCESS FOR THE PREPARATION OF CYCLIC SPIROPIPERIDINES	ASTRAZENECA AB (SE)	2009-01-22	—	—	WO	disclosed
US-20080167332-A1	Novel Compounds 243	ASTRAZENECA AB (SE)	2008-07-10	—	—	US	disclosed
US-20080167332-A1	Novel Compounds 243	ASTRAZENECA AB (SE)	2008-07-10	—	—	US	disclosed
US-20080167332-A1	Novel Compounds 243	ASTRAZENECA AB (SE)	2008-07-10	—	—	US	disclosed
WO-2008010765-A1	NOVEL TRICYCLIC SPIROPIPERIDINE COMPOUNDS, THEIR SYNTHESIS AND THEIR USES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY	ASTRAZENECA AB (SE)	2008-01-24	—	—	WO	disclosed
WO-2008010765-A1	NOVEL TRICYCLIC SPIROPIPERIDINE COMPOUNDS, THEIR SYNTHESIS AND THEIR USES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY	ASTRAZENECA AB (SE)	2008-01-24	—	—	WO	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20080167332-A1	Novel Compounds 243	UGT1A10, ABCG2, VKORC1L1	KDM4E 2805/4885MAPT 3192/4885MEN1 787/4885
US-20090176815-A1	Novel Tricyclic Spiropiperidine Compounds, Their Synthesis and Their Uses as Modulators of Chemokine Receptor Activity	ACKR3, CCR2, CCR5	KDM4E 4622/4885MAPT 4798/4885MEN1 3073/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.